PDCD1 and neoplasm: Tanaka et al. demonstrated that esophageal patients with PD-L2-positive tumor had significantly inferior responses to chemotherapy suggesting that PD-1/PD-Ls pathway might be an immunological mechanism associated with resistance to chemotherapy in esophageal cancer patients (32).